Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
JACC · 2024-08 · 84 (8) · 696-708
DOI: 10.1016/j.jacc.2024.06.016 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JACC, 2024-08. Verfasst von Daniel Edmonston und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Du…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glomerular Filtration Rate, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Boehringer Ingelheim Corp USA.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose cotransporter 2 inhibitors (SGLT2i), a first-line therapy for this population, are needed. OBJECTIVES: The authors compared kidney and cardiovascular outcomes for new users of SGLT2i and GLP-1 RAs with T2D. METHODS: Using propensity score overlap weighting, we analyzed electronic health record data from 20 U.S. health systems contributing to PCORnet between 2015 and 2020. The primary kidney outcome was a composite of sustained 40% estimated glomerular filtration rate (eGFR) decline, incident end-stage kidney disease, or all-cause mortality over 2 years or until censoring. In addition, we examined cardiovascular and safety outcomes. RESULTS: The weighted study cohort included 35,004 SGLT2i and 47,268 GLP-1 RA initiators. Over a median of 1.2 years, the primary outcome did not differ between treatments (HR: 0.91; 95% CI: 0.81-1.02), although SGLT2i were associated with a lower risk of 40% eGFR decline (HR: 0.77; 95% CI: 0.65-0.91). Risks of mortality (HR: 1.08; 95% CI: 0.92-1.27), a composite of stroke, myocardial infarction, or death (HR: 1.03; 95% CI: 0.93-1.14), and heart failure hospitalization (HR: 0.95; 95% CI: 0.80-1.13) did not differ. Genital mycotic infections were more common for SGLT2i initiators, but other safety outcomes did not differ. The results were similar regardless of chronic kidney disease status. CONCLUSIONS: SGLT2i and GLP-1 RAs led to similar kidney and cardiovascular outcomes in people with T2D, though SGLT2i initiation was associated with a lower risk of 40% eGFR decline. (Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease; NCT05465317).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina USA. Electron…
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina USA.
- Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Family and Preventive Medicine and the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
- Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- Boehringer Ingelheim Corp USA
Zitieren
APA
Edmonston, D., Mulder, H., Lydon, E., Chiswell, K., Lampron, Z., Shay, C., Marsolo, K., Shah, R. C., Jones, W. S., Gordon, H., Hwang, W., Ayoub, I., Ford, D., Chamberlain, A., Rao, A., Fonseca, V., Chang, A., Ahmad, F., Hung, A., …, & Pagidipati, N. (2024). Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. JACC, 84(8), 696-708. https://doi.org/10.1016/j.jacc.2024.06.016
Vancouver
Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, et al. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. JACC. 2024;84(8):696-708. doi:10.1016/j.jacc.2024.06.016
BibTeX
@article{Edmonston2024,
author = {Edmonston, Daniel and Mulder, Hillary and Lydon, Elizabeth and Chiswell, Karen and Lampron, Zachary and Shay, Christina and Marsolo, Keith and Shah, Raj C and Jones, W Schuyler and Gordon, Howard and Hwang, Wenke and Ayoub, Isabelle and Ford, Daniel and Chamberlain, Alanna and Rao, Ajaykumar and Fonseca, Vivian and Chang, Alexander and Ahmad, Faraz and Hung, Adriana and Hunt, Kelly and Butler, Javed and Bosworth, Hayden B and Pagidipati, Neha},
title = {Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes},
journal = {JACC},
year = {2024},
volume = {84},
number = {8},
pages = {696--708},
doi = {10.1016/j.jacc.2024.06.016}
}
EUVIMED